Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2024European Journal of Clinical Microbiology & Infectious DiseasesOpen Access

In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMatteo BoattiniGBGabriele BiancoSCSara Comini

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Boattini et al. (2024) studied this question.

synapsesocial.com/papers/6a6bc31af66cb1697bf40e7ahttps://doi.org/10.1007/s10096-024-04958-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)2022 · 69 citations
  2. 2Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)2023 · 41 citations
  3. 3Mortality in KPC-producingKlebsiella pneumoniaebloodstream infections: a changing landscape2023 · 44 citations
  4. 4Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study2021 · 275 citations
  5. 5Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments2022 · 40 citations